Chief Medical Officer
Humphrey Gardner is the chief medical officer at Silicon Therapeutics. Dr. Gardner joined Silicon from Evelo Biosciences where he served as chief of medical oncology and led oncology discovery. Dr. Gardner also led the investigational new drug and clinical development of the company’s first microbial cancer immune therapy.
Dr. Gardner previously served as vice president of early clinical development in both infection and in oncology at AstraZeneca and as senior vice president of clinical development at Karyopharm. Prior to these appointments, Dr. Gardner led the oncology translational laboratories at Novartis and various discovery and translational programs at Biogen. Before joining industry, he was an assistant professor of cell biology at The Scripps Research Institute. Dr. Gardner earned a bachelor of arts degree in biochemistry and his bachelor of medicine, bachelor of surgery degrees at the University of Cambridge in Cambridge, U.K. Dr. Gardner did specialty training in anatomic pathology at Beth Israel Hospital, Harvard Medical School in Boston, Mass. He completed his postdoctoral fellowship at the Whitehead Institute in Cambridge, Mass. Dr. Gardner has more than 100 publications and patents in fields including oncology, neuroscience, rheumatology and diagnostics. He earned a master of science degree in bioinformatics from Brandeis University, in Waltham, Mass.